A guide to a custom-tailored era of heart failure treatment

By American Heart Association News

Westend61, Getty Images
(Westend61, Getty Images)

The future of heart failure treatment lies in what's known as precision medicine, according to a new report that seeks to guide doctors along this medical frontier.

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. Precision medicine looks at individual variations in genetics, metabolism and other factors to provide tailored treatment.

Such an approach could identify people more likely to develop heart failure and pinpoint which medications and other therapies could be most effective. The report describes how variations in genes, biomarkers in the blood, or bacteria in the gut can predict the risk of heart failure and how a person may respond to treatments.

The guidance was published Thursday as an American Heart Association scientific statement in the journal Circulation: Genomic and Precision Medicine.

More than 6.5 million people in the United States have heart failure; 1 million new cases are diagnosed annually, according to the statement.

Doctors already use some aspects of precision medicine routinely. For example, the blood level of a biomarker called B-type natriuretic peptide indicates whether heart failure is worsening or if treatments are working. It also can help determine whether symptoms such as shortness of breath are because of heart failure or something else.

"The use of biomarkers is probably the most advanced aspect of precision medicine currently used in the treatment of heart failure," Dr. Sharon Cresci, chair of the statement writing group, said in a news release.  She is associate professor of medicine and genetics at Washington University in St. Louis. "Most others are still in their infancy, and we hope in the future to combine multiple aspects of precision medicine to improve patient care and outcomes."

Medications have improved the prognosis for people with heart failure in recent decades. Cresci explained, "Major clinical trials often treat large numbers of patients with one medication, and if there is a positive result, the use of that medication is likely to be incorporated into guidelines for treatment."  

But the one-size-fits-all approach has limits. Cresci said that within a large group of clinical trial participants, some people often show no response or suffer side effects. "Precision medicine approaches can help us identify who those non-responders or adverse responders are likely to be so we can find different treatment options for them," she said.

To do this, it is important that clinical trials enroll a diverse group of participants, she said. "People with different racial and ethnic ancestry have different genetic variants. Therefore, they may not have the same response to a medication or other treatment."

The promise of precision medicine also hinges on infrastructure, Cresci said. "We'll need specialized training for clinicians, processes for sharing information across large databases and guarantees for patient privacy."

Nevertheless, she added, "It's exciting to realize the potential lifesaving innovations on the horizon through precision medicine."

If you have questions or comments about this story, please email [email protected].


American Heart Association News Stories

American Heart Association News covers heart disease, stroke and related health issues. Not all views expressed in American Heart Association News stories reflect the official position of the American Heart Association. Statements, conclusions, accuracy and reliability of studies published in American Heart Association scientific journals or presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect the American Heart Association’s official guidance, policies or positions.

Copyright is owned or held by the American Heart Association, Inc., and all rights are reserved. Permission is granted, at no cost and without need for further request, for individuals, media outlets, and non-commercial education and awareness efforts to link to, quote, excerpt from or reprint these stories in any medium as long as no text is altered and proper attribution is made to American Heart Association News.

Other uses, including educational products or services sold for profit, must comply with the American Heart Association’s Copyright Permission Guidelines. See full terms of use. These stories may not be used to promote or endorse a commercial product or service.

HEALTH CARE DISCLAIMER: This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. If you are in the United States and experiencing a medical emergency, call 911 or call for emergency medical help immediately.